You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (7) Apply Prescription medicines filter
- Remove Safety of medicines & medical devices filter Safety of medicines & medical devices (0)
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Safety of medicines & medical devices filter Safety of medicines & medical devices
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012
Fexofenadine and loperamide: proposed advisory statements for medicines
Closed on 4 June 2012
Regulation of new excipients in topical non-prescription medicines
Closed on 16 December 2005